144 related articles for article (PubMed ID: 37621251)
1. Study on the allosteric activation mechanism of SHP2
Liu L; Cheng Y; Zhang Z; Li J; Geng Y; Li Q; Luo D; Liang L; Liu W; Hu J; Ouyang W
Phys Chem Chem Phys; 2023 Sep; 25(35):23588-23601. PubMed ID: 37621251
[TBL] [Abstract][Full Text] [Related]
2. Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect.
Cheng Y; Ouyang W; Liu L; Tang L; Zhang Z; Yue X; Liang L; Hu J; Luo T
Phys Chem Chem Phys; 2024 Mar; 26(12):9155-9169. PubMed ID: 38165855
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations.
Wang Q; Zhao WC; Fu XQ; Zheng QC
Front Chem; 2020; 8():597495. PubMed ID: 33330386
[TBL] [Abstract][Full Text] [Related]
4. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.
Anselmi M; Hub JS
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588
[TBL] [Abstract][Full Text] [Related]
5.
Marasco M; Kirkpatrick JP; Carlomagno T
Biomol NMR Assign; 2020 Oct; 14(2):179-188. PubMed ID: 32236803
[TBL] [Abstract][Full Text] [Related]
6. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2
Zhou L; Feng Y; Ma YC; Zhang Z; Wu JW; Du S; Li WY; Lu XH; Ma Y; Wang RL
J Mol Graph Model; 2021 Mar; 103():107807. PubMed ID: 33338846
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of SHP2 activation by PD-1 stimulation.
Marasco M; Berteotti A; Weyershaeuser J; Thorausch N; Sikorska J; Krausze J; Brandt HJ; Kirkpatrick J; Rios P; Schamel WW; Köhn M; Carlomagno T
Sci Adv; 2020 Jan; 6(5):eaay4458. PubMed ID: 32064351
[TBL] [Abstract][Full Text] [Related]
8. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.
Calligari P; Santucci V; Stella L; Bocchinfuso G
Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129
[TBL] [Abstract][Full Text] [Related]
9. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
[TBL] [Abstract][Full Text] [Related]
10. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.
Anselmi M; Hub JS
Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231
[TBL] [Abstract][Full Text] [Related]
11. Phosphotyrosine couples peptide binding and SHP2 activation via a dynamic allosteric network.
Marasco M; Kirkpatrick J; Nanna V; Sikorska J; Carlomagno T
Comput Struct Biotechnol J; 2021; 19():2398-2415. PubMed ID: 34025932
[TBL] [Abstract][Full Text] [Related]
12. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Distinct Binding and Activation Mechanisms for Different CagA Oncoproteins and SHP2 by Molecular Dynamics Simulations.
Wang Q; Zhao WC; Fu XQ; Zheng QC
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562680
[TBL] [Abstract][Full Text] [Related]
14. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
[TBL] [Abstract][Full Text] [Related]
15. Probing the Immunoreceptor Tyrosine-Based Inhibition Motif Interaction Protein Partners with Proteomics.
Gao Y; Xing S; Hu L
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731468
[TBL] [Abstract][Full Text] [Related]
16. Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors.
Xu X; Masubuchi T; Cai Q; Zhao Y; Hui E
Elife; 2021 Nov; 10():. PubMed ID: 34734802
[TBL] [Abstract][Full Text] [Related]
17. Revealing Allosteric Mechanism of Amino Acid Binding Proteins from Open to Closed State.
Shi Q; Liu L; Duan H; Jiang Y; Luo W; Sun G; Ge Y; Liang L; Liu W; Shi H; Hu J
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894619
[TBL] [Abstract][Full Text] [Related]
18. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
19. Gain-of-Function SHP2 E76Q Mutant Rescuing Autoinhibition Mechanism Associated with Juvenile Myelomonocytic Leukemia.
Rehman AU; Rafiq H; Rahman MU; Li J; Liu H; Luo S; Arshad T; Wadood A; Chen HF
J Chem Inf Model; 2019 Jul; 59(7):3229-3239. PubMed ID: 31244092
[TBL] [Abstract][Full Text] [Related]
20. Dual Allosteric Inhibition of SHP2 Phosphatase.
Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
